Form 4: Vaxcyte SVP, Finance, Elvia Cowan, Executes Stock Option and Sells Shares

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., exercised stock options and sold shares to cover tax obligations, according to a Form 4 filing.

Summary

• On September 3, 2024, Elvia Cowan, SVP of Finance at Vaxcyte, Inc. [PCVX], exercised stock options to acquire 5,000 shares of common stock at a price of $25.92 per share.
• Cowan then sold 5,000 shares of common stock at $107.67 per share.
• Additionally, 1,145 shares were surrendered to cover tax withholding obligations at a price of $110.15.
• Following these transactions, Cowan directly owns 11,578 shares of Vaxcyte common stock and holds options for 114,000 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reflects standard insider trading activity under a pre-arranged plan.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It's common for executives to exercise stock options and sell shares for personal financial management and to cover tax obligations.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• The transactions are typical for executives who receive stock options as part of their compensation packages.
• Similar filings can be observed across the pharmaceutical and biotechnology industries, including companies like Pfizer (PFE), Moderna (MRNA), and BioNTech (BNTX).

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates